The latest price target for Impel Pharmaceuticals (NASDAQ: IMPL) was reported by JonesTrading on August 25, 2022. The analyst firm set a price target for $26.00 expecting IMPL to rise to within 12 months (a possible 227.46% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Impel Pharmaceuticals (NASDAQ: IMPL) was provided by JonesTrading, and Impel Pharmaceuticals initiated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Impel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Impel Pharmaceuticals was filed on August 25, 2022 so you should expect the next rating to be made available sometime around August 25, 2023.

While ratings are subjective and will change, the latest Impel Pharmaceuticals (IMPL) rating was a initiated with a price target of $0.00 to $26.00. The current price Impel Pharmaceuticals (IMPL) is trading at is $7.94, which is within the analyst's predicted range.